Neuroleptic Malignant Syndrome malady

NINDS: Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction. In most cases, the disorder develops within the first 2 weeks of treatment with the drug; however, the disorder may develop any time during the therapy period. The syndrome can also occur in people taking anti-Parkinsonism drugs known as dopaminergics if those drugs are discontinued abruptly.³¹

MalaCards: Neuroleptic Malignant Syndrome is related to malignant hyperthermia and cerebritis. An important gene associated with Neuroleptic Malignant Syndrome is NHLRC1 (NHL repeat containing 1), and among its related pathways are Amine ligand-binding receptors and Neuroactive ligand-receptor interaction. The drugs bromocriptine and dantrolene sodium and the compounds yohimbine and dantrolene have been mentioned in the context of this disorder. Related mouse phenotypes are muscle and homeostasis/metabolism.

Wikipedia: Neuroleptic malignant syndrome (NMS) is a life-threatening neurological disorder most often caused by an...⁴⁴ more...

Aliases & Descriptions:

neuroleptic malignant syndrome 6 30 31 8 32 43

Diseases related to neuroleptic malignant syndrome by text searches and GeneDecks gene sharing:

(show top 50)    (show all 215)

id	Related Disease	Score	Top Affiliating Genes
1	malignant hyperthermia	27.6	PIK3C2A, CHKB, MB, GPT, HTR2A, RYR1
2	cerebritis	26.2	PIK3C2A, CHKA, CHKB, MB, HTR1A, HTR2A
3	short-chain acyl-coa dehydrogenase deficiency	13.6	PIK3C2A, CHKA
4	adult dermatomyositis	13.5	PIK3C2A, CHKB
5	bronchiolitis obliterans organizing pneumonia	13.4	PIK3C2A, CHKA
6	acute kidney tubular necrosis	13.4	PIK3C2A, MB
7	creatine phosphokinase, elevated serum	13.3	PIK3C2A, CHKB, MB
8	hypocalcemia	13.3	PIK3C2A, CHKA, CHKB
9	gas gangrene	13.3	PIK3C2A, CHKB, MB
10	compartment syndrome	13.3	CHKA, CHKB, MB
11	hypersomnia	13.3	CHKB, CYP2D6
12	ullrich congenital muscular dystrophy	13.3	PIK3C2A, CHKA, CHKB
13	coronary artery vasospasm	13.3	CHKB, HTR2A
14	intermediate coronary syndrome	13.3	PIK3C2A, MB
15	tic disorder	13.2	HTR2A, DRD2
16	duchenne muscular dystrophy	13.2	PIK3C2A, CHKB, MB
17	bronchiolitis obliterans	13.2	PIK3C2A, CHKA, CHKB
18	ectopic pregnancy	13.2	PIK3C2A, CHKB, MB
19	muscle disorders	13.2	CHKA, CHKB, RYR1
20	necrotizing fasciitis	13.2	PIK3C2A, GPT
21	viral pneumonia	13.2	CHKB, GPT
22	cardiac rupture	13.1	CHKB, NPPB
23	congenital heart block	13.1	PIK3C2A, NPPB
24	nicotine dependence	13.1	ANKK1, DRD2, CYP2D6
25	ocular hypotension	13.1	HTR1A, HTR2A
26	opiate dependence	13.0	ANKK1, GPT, DRD2
27	polymyositis	13.0	PIK3C2A, CHKA, CHKB, MB
28	neuromuscular disease	13.0	CHKB, MB, RYR1
29	inferior myocardial infarction	13.0	PIK3C2A, NPPB
30	gastroparesis	13.0	HTR3A, DRD2, CYP2D6
31	social phobia	13.0	HTR1A, HTR3A, DRD2
32	antisocial personality disorder	13.0	HTR2A, DRD2
33	central core myopathy	13.0	RYR1, RYR3
34	malignant hyperthermia susceptibility	13.0	PIK3C2A, HTR2A, RYR1
35	cramps	13.0	PIK3C2A, MB, GPT
36	wilson disease	13.0	GPT, DRD2, CYP2D6
37	central nervous system disease	13.0	HTR2A, F2RL1, CYP2D6
38	phobia	13.0	HTR1A, HTR3A, DRD2
39	trichinosis	12.9	PIK3C2A, POMC
40	amnestic disorder	12.9	HTR1A, HTR3A
41	multiple chemical sensitivity	12.9	GPT, CYP2D6
42	aggressive digital papillary adenocarcinoma	12.9	HTR1A, HTR3A, DRD2
43	disseminated intravascular coagulation	12.9	PIK3C2A, MB, GPT
44	myasthenia gravis	12.9	CHKB, MB, CYP2D6, RYR1
45	progressive supranuclear palsy	12.8	HTR1A, HTR3A, DRD2
46	dyskinesia of esophagus	12.8	HTR1A, HTR2A, DRD2, CYP2D6
47	congenital myasthenic syndrome	12.8	CHKB, MB, CYP2D6, RYR1
48	ventricular fibrillation	12.8	CHKB, MB, NPPB
49	schizoaffective disorder	12.8	HTR1A, HTR2A, DRD2, CYP2D6
50	catecholaminergic polymorphic ventricular tachycardia	12.8	PIK3C2A, NPPB, RYR1

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 bromocriptine, bromocriptine mesylate, dantrolene, dantrolene sodium

MGI Mouse Phenotypes related to neuroleptic malignant syndrome:

²⁵

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	muscle phenotype	MP:0005369	7.2	CHKB, NHLRC1, RYR3, RYR1, NPPB, DRD2
2	homeostasis/metabolism phenotype	MP:0005376	7.0	F2RL1, DRD2, POMC, RYR1, HTR3A, HTR1A
3	behavior/neurological phenotype	MP:0005386	6.2	NHLRC1, RYR3, RYR1, POMC, DRD2, F2RL1

Articles related to neuroleptic malignant syndrome:

(show all 40)

id	Title	Authors	Year	Affiliating Genes
1	Postmortem molecular screening for mutations in ryano dine receptor type 1 (RYR1) gene in psychiatric patients suspected of having di ed of neuroleptic malignant syndrome. (19931341)	Sato T.... Suzuki K.	2010	RYR1
2	Neuroleptic malignant syndrome or a statin drug react ion? A case report. (19952877)	Cooper J.M.... Jones A.L.	2009	CHKB
3	Neuroleptic malignant syndrome in children and adoles cents on atypical antipsychotic medication: a review. (19702493)	Neuhut R.... Silva R.	2009	PIK3C2A
4	Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? (19149529)	Odagaki Y.	2009	HTR1A
5	Cerebral salt-wasting syndrome in a patient with neuroleptic malignant syndrome. (17210819)	Lenhard T.... Schwab S.	2007	NPPB
6	Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl. (17453880)	Erermis S.... Ercan E.S.	2007	PIK3C2A
7	Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. (17701031)	Kato D.... Hirayasu Y.	2007	CYP2D6
8	Neuroleptic malignant syndrome: a review and report of six cases. (17214072)	Kasantikul D.... Kanchanatawan B.	2006	PIK3C2A
9	Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration. (17119106)	Norris B.... Seale J.P.	2006	CHKB
10	CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report. (16048458)	Kato D.... Hirayasu Y.	2005	CYP2D6
11	Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. (15840734)	Aruna A.S.... Murungi J.H.	2005	GPT
12	Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. (15094790)	Kishida I.... Kosaka K.	2004	DRD2
13	Mutation analysis of the ryanodine receptor gene isoform 3 (RYR3) in recurrent neuroleptic malignant syndrome. (15232352)	Dettling M.... Steinlein O.K.	2004	RYR3
14	Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene. (12605103)	Kishida I.... Kosaka K.	2003	DRD2, ANKK1
15	Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. (12555236)	Mihara K.... Kaneko S.	2003	DRD2, ANKK1
16	High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. (12006894)	Hermesh H.... Weizman A.	2002	CHKA
17	Three patients with isolated adrenocorticotropin deficiency presenting with neuroleptic malignant syndrome-like symptoms. (11446676)	Sekijima Y.... Ikeda S.I.	2001	POMC
18	Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. (11579007)	Suzuki A.... Kaneko S.	2001	DRD2
19	Neuroleptic malignant syndrome associated with amoxapine and lithium in an older adult. (10907803)	Gupta S.... Racaniello A.A.	2000	PIK3C2A
20	Neuroleptic malignant syndrome associated with olanza pine therapy: a case report. (11074330)	Stanfield S.C.... Privette T.	2000	HTR3A
21	Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. (11204351)	Kawanishi C.... Kosaka K.	2000	CYP2D6
22	CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. (9892857)	Iwahashi K.... Igarashi K.	1999	CYP2D6
23	Severe catatonia and neuroleptic malignant syndrome: report of 3 cases. (10561954)	Kasantikul D.... Kanchananakhin P.	1999	MB
24	Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. (9734554)	Kawanishi C.... Kosaka K.	1998	HTR1A, HTR2A
25	Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. (9804127)	Kawanishi C.... Kosaka K.	1998	CYP2D6
26	Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. (9323326)	Kawanishi C.... Kosaka K.	1997	CYP2D6
27	The obscure autopsy and neuroleptic malignant syndrome. (9029927)	Lowe J.W.	1997	MB
28	Neuroleptic malignant syndrome with risperidone. (9165568)	Gleason P.P.... Conigliaro R.L.	1997	DRD2
29	Neuroleptic malignant syndrome, syndrome malin (8904246)	Takahashi A.... Murasaki M.	1996	NHLRC1
30	The neuroleptic malignant syndrome (NMS). A report o f a clinical case with a protracted and recurrent course. A review of the liter ature (8610025)	Marelli A.... Boldori L.	1996	PIK3C2A
31	Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome. (8780858)	Ueno S.... Sano A.	1996	CYP2D6
32	No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia. (8981316)	Miyatake R.... Suwaki H.	1996	RYR1
33	A case of acute renal failure in neuroleptic malignant syndrome associated with rhabdomyolysis--possible contributing role of hyperreninemia (7815749)	Fujisawa K.... Nagase M.	1994	PIK3C2A
34	Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine? (7955001)	Kelly D.... Brull S.J.	1994	CHKB
35	Clinical study of neuroleptic malignant syndrome in demented patients--examination of our case and reported cases (7999444)	Kimura T.... Yoshida H.	1994	PIK3C2A
36	An atypical course of neuroleptic malignant syndrome. (8006200)	Schneiderhan M.E.... Marken P.A.	1994	PIK3C2A
37	The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. (8101383)	O'Dwyer A.M.... Sheppard N.P.	1993	CHKB
38	Neuroleptic malignant syndrome: a dangerous complication of neuroleptic therapy. (8445278)	Byrd C.	1993	PIK3C2A
39	Neuroleptic malignant syndrome associated with clozap ine monotherapy. (8247922)	Thornberg S.A.... Ereshefsky L.	1993	F2RL1
40	The relationship between syndrome malin and neuroleptic malignant syndrome, and rhabdomyolysis (1970519)	Sudo K.... Tashiro K.	1990	NHLRC1

Genes related to neuroleptic malignant syndrome according to GeneCards:

(show all 18)

id	Symbol	Description	Score	GeneCards Section Context
1	NHLRC1	NHL repeat containing 1	11.0	Publications
2	PIK3C2A	phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha	11.0	Publications
3	CYP2D6	cytochrome P450, family 2, subfamily D, polypeptide 6	11.0	Publications
4	CHKB	choline kinase beta	11.0	Publications
5	CHKA	choline kinase alpha	11.0	Publications
6	DRD2	dopamine receptor D2	11.0	Publications
7	MB	myoglobin	11.0	Publications
8	HTR1A	5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled	11.0	Publications
9	NMS	neuromedin S	11.0
10	ANKK1	ankyrin repeat and kinase domain containing 1	11.0	Publications
11	F2RL1	coagulation factor II (thrombin) receptor-like 1	11.0	Publications
12	RYR1	ryanodine receptor 1 (skeletal)	11.0	Publications
13	POMC	proopiomelanocortin	11.0	Publications
14	RYR3	ryanodine receptor 3	11.0	Publications
15	NPPB	natriuretic peptide B	11.0	Publications
16	HTR3A	5-hydroxytryptamine (serotonin) receptor 3A, ionotropic	11.0	Publications
17	HTR2A	5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled	11.0	Publications
18	GPT	glutamic-pyruvate transaminase (alanine aminotransferase)	11.0	Publications

Pathways related to neuroleptic malignant syndrome according to GeneDecks:

id	Pathway	Score	Top Affiliating Genes
1	Amine ligand-binding receptors38	9.0	HTR1A, HTR2A, DRD2
2	Neuroactive ligand-receptor interaction20	8.8	HTR1A, HTR2A, F2RL1, DRD2
3	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics34	8.8	HTR1A, HTR2A, HTR3A
4	Intracellular Calcium Signaling36	7.6	RYR3, RYR1, HTR3A, HTR2A, HTR1A

Compounds related to neuroleptic malignant syndrome according to GeneDecks:

(show top 50)    (show all 254)

id	Compound	Score	Top Affiliating Genes
1	yohimbine32 9 9	12.1	HTR1A, DRD2, CYP2D6
2	dantrolene32 9 9	11.7	MB, CHKB, PIK3C2A, RYR1
3	succinylcholine32 9 9	11.7	RYR1, MB, CHKB, PIK3C2A
4	alpha-hydroxybutyrate32	9.7	GPT, CHKB, MB, PIK3C2A
5	halothane32 9 9	11.5	CHKB, MB, RYR1, PIK3C2A, CYP2D6
6	fluvastatin32 34 9 9	12.3	CHKB, GPT, CYP2D6, MB, PIK3C2A
7	Pipotiazine9 9	10.3	DRD2, HTR2A, HTR1A, CYP2D6
8	sertindole32 9 9	11.2	DRD2, CYP2D6, HTR2A, HTR1A
9	piperazine32 9 9	11.2	HTR1A, HTR2A, DRD2, CYP2D6
10	trimipramine32 34 9 9	12.0	HTR2A, CYP2D6, DRD2, HTR1A
11	iloperidone32 34	9.9	HTR2A, CYP2D6, HTR3A, HTR1A
12	granisetron32 9 9	10.9	HTR2A, CYP2D6, DRD2, HTR3A
13	pravastatin32 34 9 18 9	12.9	NPPB, PIK3C2A, CHKA, CYP2D6, GPT, CHKB
14	amperozide32	8.9	HTR1A, HTR2A, HTR3A, DRD2
15	mcpp32	8.9	CYP2D6, HTR3A, HTR2A, HTR1A
16	dopamine32 9 18 9	11.9	DRD2, F2RL1, HTR3A, HTR1A, MB, CHKB
17	spiperone32	8.9	HTR2A, HTR1A, HTR3A, DRD2
18	ropinirole32 9 9	10.9	CYP2D6, HTR1A, HTR2A, DRD2
19	atorvastatin32 34 9 18 9	12.9	CHKA, PIK3C2A, CHKB, GPT, NPPB, CYP2D6
20	ritanserin32	8.9	DRD2, HTR3A, HTR2A, HTR1A
21	pindolol32 9 9	10.9	HTR2A, HTR3A, HTR1A, CYP2D6
22	creatinine32	8.8	NPPB, POMC, CHKA, MB, RYR1
23	mianserin32 9 9	10.8	CYP2D6, HTR3A, HTR1A, HTR2A
24	bromocriptine32 9 9	10.8	DRD2, POMC, PIK3C2A, HTR1A, HTR2A
25	perphenazine32 34 9 9	11.8	CYP2D6, DRD2, HTR2A, HTR3A
26	lisuride32 9 9	10.8	CYP2D6, HTR1A, HTR2A, DRD2
27	cocaine32 9 9	10.8	CHKB, GPT, PIK3C2A, MB, POMC, CYP2D6
28	ergotamine32 9 9	10.7	HTR1A, HTR3A, DRD2, HTR2A
29	ipsapirone32	8.7	HTR3A, HTR2A, HTR1A, POMC
30	ketanserin32	8.7	HTR2A, DRD2, HTR1A, HTR3A
31	buspirone32 9 9	10.7	DRD2, HTR1A, HTR2A, CYP2D6, HTR3A
32	aripiprazole32 34 9 18 9	12.7	DRD2, HTR3A, HTR1A, CYP2D6, HTR2A
33	ziprasidone32 9 9	10.7	DRD2, HTR3A, HTR2A, CYP2D6, HTR1A
34	quetiapine32 9 18 9	11.6	CYP2D6, DRD2, HTR3A, HTR2A, HTR1A
35	nefazodone34 32 9 9	11.6	HTR1A, HTR2A, HTR3A, CYP2D6
36	prednisolone32 9 9	10.6	MB, GPT, NPPB, CHKB, PIK3C2A, POMC
37	fluoxetine32 34 9 9	11.6	HTR2A, HTR3A, DRD2, CYP2D6, HTR1A
38	fenfluramine32 9 9	10.5	POMC, CYP2D6, HTR1A, HTR3A, HTR2A
39	venlafaxine32 34 9 18 9	12.5	HTR1A, HTR2A, HTR3A, CYP2D6
40	thyroxine32 18	9.5	GPT, CHKA, NPPB, CHKB, POMC, MB
41	chlorpromazine32 9 9	10.5	CYP2D6, DRD2, HTR3A, HTR2A, HTR1A, CHKB
42	mirtazapine32 34 9 9	11.5	CYP2D6, POMC, HTR3A, HTR2A
43	maoa32	8.4	DRD2, HTR2A, POMC, HTR1A
44	olanzapine32 34 9 18 9	12.2	ANKK1, CYP2D6, CHKB, HTR1A, HTR2A, HTR3A
45	risperidone32 34 9 18 9	12.0	CHKB, GPT, HTR1A, HTR3A, DRD2, HTR2A
46	5-hydroxytryptamine32	7.9	F2RL1, DRD2, POMC, HTR1A, HTR2A, HTR3A
47	haloperidol32 34 9 9	10.7	PIK3C2A, NPPB, HTR3A, HTR2A, HTR1A, GPT
48	clozapine32 34 9 9	10.6	POMC, DRD2, F2RL1, HTR3A, HTR2A, HTR1A
49	acetylcholine32 9 18 9	10.2	PIK3C2A, POMC, NPPB, RYR1, CYP2D6, F2RL1
50	norepinephrine32 9 18 9	9.6	NPPB, RYR1, POMC, DRD2, PIK3C2A, CHKB

Cellular components related to neuroleptic malignant syndrome according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	junctional membrane complex	GO:030314	9.6	RYR1, RYR3

Biological processes related to neuroleptic malignant syndrome according to GeneDecks:

(show all 9)

id	Name	GO ID	Score	Top Affiliating Genes
1	phosphatidylethanolamine biosynthetic process	GO:006646	10.0	CHKA, CHKB
2	cellular response to caffeine	GO:071313	9.8	RYR1, RYR3
3	positive regulation of renal sodium excretion	GO:035815	9.6	NPPB, DRD2
4	negative regulation of synaptic transmission, glutamatergic	GO:051967	9.5	DRD2, HTR2A
5	positive regulation of urine volume	GO:035810	9.4	NPPB, DRD2
6	regulation of dopamine secretion	GO:014059	9.4	HTR2A, DRD2
7	response to hypoxia	GO:001666	9.2	RYR1, NPPB, DRD2, MB
8	release of sequestered calcium ion into cytosol	GO:051209	9.2	HTR2A, DRD2, RYR1
9	serotonin receptor signaling pathway	GO:007210	9.1	HTR2A, HTR3A

Molecular functions related to neuroleptic malignant syndrome according to GeneDecks:

(show all 7)

id	Name	GO ID	Score	Top Affiliating Genes
1	choline kinase activity	GO:004103	10.0	CHKA, CHKB
2	ethanolamine kinase activity	GO:004305	9.9	CHKA, CHKB
3	calcium-release channel activity	GO:015278	9.6	RYR1, RYR3
4	ryanodine-sensitive calcium-release channel activity	GO:005219	9.3	RYR1, RYR3
5	serotonin binding	GO:051378	8.9	HTR1A, HTR2A, HTR3A
6	serotonin receptor activity	GO:004993	8.8	HTR3A, HTR2A, HTR1A
7	drug binding	GO:008144	8.8	CHKA, HTR1A, HTR2A, DRD2, CYP2D6